The integration aims to expand the company’s reach beyond traditional in-vitro testing. According to Chief Commercial Officer Jamie Brannan, the merger provides a 24/7 lifeline to veterinary specialists, paired with artificial intelligence workflows designed to streamline clinical decision-making. By creating a more robust Virtual Lab ecosystem, the company intends to capture new growth avenues in the animal diagnostics market.

Investors showed a muted reaction to the announcement. Shares of Zoetis slipped 1.9% to $73.97 during Tuesday afternoon trading as the market digested the move.